Cargando…

Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis

The treatment of locally recurrent lung cancer is a major challenge for radiation-oncologists, especially with data on high-dose reirradiation being limited to small retrospective studies. The aim of the present study is to assess overall survival (OS) for patients with locally recurrent lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grambozov, Brane, Nussdorfer, Evelyn, Kaiser, Julia, Gerum, Sabine, Fastner, Gerd, Stana, Markus, Gaisberger, Christoph, Wass, Romana, Studnicka, Michael, Sedlmayer, Felix, Zehentmayr, Franz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161822/ https://www.ncbi.nlm.nih.gov/pubmed/34068043 http://dx.doi.org/10.3390/curroncol28030170

Ejemplares similares

Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer
por: Grambozov, Brane, et al.
Publicado: (2019)

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
por: Stana, Markus, et al.
Publicado: (2022)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
por: Zehentmayr, Franz, et al.
Publicado: (2020)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
por: Zellinger, Barbara, et al.
Publicado: (2021)

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation
por: Zehentmayr, Franz, et al.
Publicado: (2019)

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
por: Zellinger, Barbara, et al.
Publicado: (2020)

Boost IORT in Breast Cancer: Body of Evidence
por: Sedlmayer, Felix, et al.
Publicado: (2014)

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
por: Zehentmayr, Franz, et al.
Publicado: (2015)

Intraoperative radiotherapy (IORT) as boost in breast cancer
por: Sedlmayer, Felix, et al.
Publicado: (2017)

First clinical application of image-guided intraoperative electron radiation therapy with real time intraoperative dose calculation in recurrent rectal cancer: technical procedure
por: Roeder, Falk, et al.
Publicado: (2023)

Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
por: Fastner, Gerd, et al.
Publicado: (2022)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
por: Wurstbauer, Karl, et al.
Publicado: (2013)

Hsa-miR-375 is a predictor of local control in early stage breast cancer
por: Zehentmayr, Franz, et al.
Publicado: (2016)

DART-bid for loco-regionally advanced NSCLC: Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints
por: Wurstbauer, Karl, et al.
Publicado: (2017)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice
por: Piroth, Marc D., et al.
Publicado: (2021)

Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy
por: Stuschke, Martin, et al.
Publicado: (2013)

Expert consensus on re-irradiation for recurrent glioma
por: Krauze, Andra, et al.
Publicado: (2017)

RARE-02.RE-IRRADIATION FOR RECURRENT CRANIOPHARYNGIOMA
por: Foran, Sarah, et al.
Publicado: (2020)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Re-irradiation for locally recurrent refractory breast cancer
por: Merino, Tomas, et al.
Publicado: (2015)

Re-irradiation alternatives for recurrent high-grade glioma
por: Dong, Yuanli, et al.
Publicado: (2016)

Correction to expert consensus on re-irradiation for recurrent glioma
por: Krauze, Andra V., et al.
Publicado: (2018)

Thoracic Re-irradiation for Locally Recurrent Lung Cancer
por: Aktan, Meryem, et al.
Publicado: (2016)

Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer
por: Takeda, Kazuya, et al.
Publicado: (2021)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma
por: Kessel, Kerstin A., et al.
Publicado: (2017)

Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors
por: Lee, Jeongshim, et al.
Publicado: (2016)

Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma
por: El Shafie, Rami A., et al.
Publicado: (2018)

Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible
por: Dijkstra, Esmée A., et al.
Publicado: (2021)

Proton re-irradiation of unresectable recurrent head and neck cancers
por: Gordon, Konstantin, et al.
Publicado: (2021)

Re-irradiation for recurrent or second primary head and neck cancer
por: Lee, Hye In, et al.
Publicado: (2021)

LMAP-10 RE-IRRADIATION FOR RECURRENT ADULT DIFFUSE GLIOMA
por: Zhou, Jiangfen, et al.
Publicado: (2023)

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
por: Ciabattoni, Antonella, et al.
Publicado: (2021)

Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
por: Ciabattoni, Antonella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tjiaor2jtsmuiomen17d10d0f8